These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15615176)

  • 1. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
    Singhal BS; Geeta S; Hundalani SG; Menon S
    Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up.
    Buttinelli C; Clemenzi A; Borriello G; Denaro F; Pozzilli C; Fieschi C
    Eur J Neurol; 2007 Nov; 14(11):1281-7. PubMed ID: 17956449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
    Wawrzyniak S; Rzepiński Ł
    Neurol Neurochir Pol; 2020; 54(1):54-61. PubMed ID: 31922582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Morrissey SP; Edan G
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):52-6. PubMed ID: 17846110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
    Millefiorini E; Gasperini C; Pozzilli C; D'Andrea F; Bastianello S; Trojano M; Morino S; Morra VB; Bozzao A; Calo' A; Bernini ML; Gambi D; Prencipe M
    J Neurol; 1997 Mar; 244(3):153-9. PubMed ID: 9050955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].
    Le Page E; Leray E; Taurin G; Coustans M; Chaperon J; Edan G
    Rev Neurol (Paris); 2006 Feb; 162(2):185-94. PubMed ID: 16518258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.
    Khatri BO; Wroblewski M; Kramer J; Dukic M; Poplar A; Anderson AJ
    Curr Ther Res Clin Exp; 2006 Jan; 67(1):55-65. PubMed ID: 24678083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
    Ostberg A; Pittas F; Taylor B
    Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
    J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
    Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
    Edan G; Miller D; Clanet M; Confavreux C; Lyon-Caen O; Lubetzki C; Brochet B; Berry I; Rolland Y; Froment JC; Cabanis E; Iba-Zizen MT; Gandon JM; Lai HM; Moseley I; Sabouraud O
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):112-8. PubMed ID: 9048709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.